Eli Lilly Advances Oral GLP-1 Treatments and Plans Broader Access in India

Eli Lilly has developed Orforglipron, an oral GLP-1 medication that outperformed oral semaglutide in reducing blood sugar and promoting weight loss in a global trial involving 1,698 participants. Meanwhile, Lilly plans to expand access to its obesity and diabetes drug Mounjaro in India, emphasizing medical supervision and responsible use amid rising obesity rates. The company anticipates increased demand for GLP-1 medicines as generic semaglutide is expected to launch in India later this year.